SAN JOSE, Calif., April 6, 2012 /PRNewswire/ -- C8 MediSensors, Inc. (www.c8medisensors.com), the leader in developing non-invasive continuous glucose monitoring for people with diabetes, announced today that it has filed for CE mark approval to market the C8 MediSensors Optical Glucose Monitor™ in Europe. The monitor is currently an adjunct investigational device.
"The European Union has over 30 million people with diabetes who strive for better glycemic control to improve their health. Continuous glucose monitoring helps achieve better glycemic control but unfortunately, current methods of continuous glucose monitoring can be painful and come with high ongoing costs year after year. We plan to address that problem with technology that allows people with diabetes to measure their glucose continuously but without the pain and cost of current invasive technologies," said Paul S. Zygielbaum, Chief Operating Officer of C8 MediSensors.
C8 MediSensors uses a proven technology, Raman spectroscopy, to accurately measure glucose trans-dermally. A pain-free beam of light enters the skin and measures the unique Raman fingerprint of the glucose molecule. Readings are then sent to a display application on the user's smartphone. The C8 MediSensors Optical Glucose Monitor has been in development for over eight years.
About C8 MediSensors
Headquartered in San Jose CA, C8 MediSensors' breakthrough patent-protected technology has been developed to give people with diabetes a continuous view of their glucose levels, without the pain, inconvenience and high cost of invasive continuous glucose monitoring. Visit www.c8medisensors.com.
This document contains forward-looking statements. Any statements contained in this document that are not statements of historical fact may be deemed to be forward- looking statements, including, without limitation, statements relating to the ability to commercially market any C8 MediSensors' anticipated products, sales and company financing needs. These forward-looking statements are based upon C8 MediSensors' current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including, without limitation, risks associated with obtaining CE mark approval, market conditions, customer demand for the product, and risks and uncertainties associated with C8 MediSensors' business and finances in general. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this document. C8 MediSensors does not undertake any obligation to update any forward-looking statements as a result of new information, future events, changed assumptions or otherwise.
|SOURCE C8 MediSensors, Inc.|
Copyright©2010 PR Newswire.
All rights reserved